PubRank

Timothy R Sterling

Author PubWeight™ 157.40‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009 19.90
2 Tuberculosis. Lancet 2003 6.39
3 An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006 5.02
4 Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis 2010 3.72
5 Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol 2007 3.46
6 Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012 3.44
7 Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. J Infect Dis 2007 3.36
8 Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr 2013 2.78
9 Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis 2004 2.71
10 Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002 2.68
11 Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr 2007 2.53
12 Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012 2.50
13 Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med 2004 2.40
14 Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am J Respir Crit Care Med 2006 2.23
15 Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009 2.18
16 U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med 2012 2.18
17 A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 2012 2.16
18 Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. AIDS 2013 2.11
19 Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis 2009 2.05
20 Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis 2009 2.04
21 Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2009 1.97
22 Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis 2013 1.94
23 Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med 2015 1.86
24 CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. J Infect Dis 2005 1.81
25 Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. Arch Intern Med 2007 1.78
26 Retention among North American HIV-infected persons in clinical care, 2000-2008. J Acquir Immune Defic Syndr 2013 1.73
27 Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr 2013 1.72
28 Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis 2009 1.72
29 Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures. Clin Infect Dis 2008 1.72
30 Extensively drug-resistant tuberculosis: are we learning from history or repeating it? Clin Infect Dis 2007 1.69
31 An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS 2013 1.64
32 Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J Infect Dis 2003 1.63
33 Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003 1.53
34 Serum albumin as a prognostic indicator for HIV disease progression. AIDS Res Hum Retroviruses 2006 1.42
35 The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med 2003 1.37
36 Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004 1.36
37 Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol 2005 1.34
38 Black race, sex, and extrapulmonary tuberculosis risk: an observational study. BMC Infect Dis 2010 1.29
39 Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting. AIDS 2011 1.23
40 A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med 2002 1.23
41 Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis 2006 1.21
42 Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. J Antimicrob Chemother 2009 1.19
43 Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting? J Acquir Immune Defic Syndr 2011 1.19
44 Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis 2006 1.18
45 An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy. Clin Infect Dis 2011 1.16
46 Tuberculosis in antiretroviral treatment programs in lower income countries: availability and use of diagnostics and screening. PLoS One 2013 1.16
47 CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther 2010 1.13
48 Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. PLoS One 2011 1.10
49 Disparities in the quality of HIV care when using US Department of Health and Human Services indicators. Clin Infect Dis 2014 1.06
50 Decreased CD4+ lymphocytes and innate immune responses in adults with previous extrapulmonary tuberculosis. J Allergy Clin Immunol 2006 1.04
51 Polymorphisms in IL-1beta, vitamin D receptor Fok1, and Toll-like receptor 2 are associated with extrapulmonary tuberculosis. BMC Med Genet 2010 0.99
52 High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility. J Clin Microbiol 2011 0.98
53 Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy. AIDS Res Hum Retroviruses 2013 0.98
54 Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. J Infect 2013 0.98
55 Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis 2013 0.97
56 Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy. Epidemiology 2010 0.96
57 Increased frequency of regulatory T cells and T lymphocyte activation in persons with previously treated extrapulmonary tuberculosis. Clin Vaccine Immunol 2011 0.96
58 The relationship between injection and noninjection drug use and HIV disease progression. J Subst Abuse Treat 2011 0.96
59 Race, kidney disease progression, and mortality risk in HIV-infected persons. Clin J Am Soc Nephrol 2010 0.95
60 Use of DNA fingerprinting to investigate a multiyear, multistate tuberculosis outbreak. Emerg Infect Dis 2002 0.95
61 Pharmacokinetics of rifapentine in children. Pediatr Infect Dis J 2006 0.93
62 CD4+/CD8+ ratio, age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy. AIDS 2016 0.93
63 Cross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators. J Clin Epidemiol 2008 0.91
64 Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention Among HIV-Infected Adults in North America. Am J Epidemiol 2015 0.90
65 Prognostic factors for survival differ according to CD4+ cell count among HIV-infected injection drug users: pre-HAART and HAART eras. J Acquir Immune Defic Syndr 2005 0.90
66 Reversible posterior leukoencephalopathy in an HIV-infected patient with thrombotic thrombocytopenic purpura. Scand J Infect Dis 2002 0.90
67 Antiretroviral therapy initiation before, during, or after pregnancy in HIV-1-infected women: maternal virologic, immunologic, and clinical response. PLoS One 2009 0.90
68 Sex differences in HIV outcomes in the highly active antiretroviral therapy era: a systematic review. AIDS Res Hum Retroviruses 2014 0.88
69 Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States. AIDS Patient Care STDS 2010 0.88
70 Accuracy of pharmacy and coded-diagnosis information in identifying tuberculosis in patients with rheumatoid arthritis. Pharmacoepidemiol Drug Saf 2012 0.86
71 HIV in the workplace in Botswana: incidence, prevalence, and disease severity. AIDS Res Hum Retroviruses 2007 0.86
72 Novel human genetic variants associated with extrapulmonary tuberculosis: a pilot genome wide association study. BMC Res Notes 2011 0.85
73 Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration. J Acquir Immune Defic Syndr 2015 0.85
74 Active cocaine use is associated with lack of HIV-1 virologic suppression independent of nonadherence to antiretroviral therapy: use of a rapid screening tool during routine clinic visits. AIDS Care 2012 0.85
75 Higher Time-Updated Body Mass Index: Association With Improved CD4+ Cell Recovery on HIV Treatment. J Acquir Immune Defic Syndr 2016 0.85
76 Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicenter cohort study. AIDS Res Hum Retroviruses 2012 0.84
77 The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy. AIDS 2016 0.83
78 Duration of anti-tuberculosis therapy and timing of antiretroviral therapy initiation: association with mortality in HIV-related tuberculosis. PLoS One 2013 0.83
79 Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis. AIDS 2013 0.83
80 Treatment of latent tuberculosis infection: challenges and prospects. Clin Chest Med 2005 0.82
81 Drug-resistant tuberculosis in New York City: lessons to remember. Clin Infect Dis 2006 0.82
82 Sociodemographic factors predict early discontinuation of HIV non-nucleoside reverse transcriptase inhibitors and protease inhibitors. J Natl Med Assoc 2008 0.81
83 Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones. Int J Antimicrob Agents 2013 0.81
84 Hemoglobin may contribute to sex differences in mortality among HIV-infected persons in care. PLoS One 2012 0.81
85 Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. J Acquir Immune Defic Syndr 2005 0.80
86 Treatment of latent tuberculosis infection in HIV: shorter or longer? Curr HIV/AIDS Rep 2012 0.80
87 Timing of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for Testing and Treatment. J Acquir Immune Defic Syndr 2016 0.80
88 Abnormal immune responses in persons with previous extrapulmonary tuberculosis in an in vitro model that simulates in vivo infection with Mycobacterium tuberculosis. Clin Vaccine Immunol 2012 0.80
89 Virologic, immunologic and clinical responses in foreign-born versus US-born HIV-1 infected adults initiating antiretroviral therapy: an observational cohort study. PLoS One 2012 0.78
90 Current drug use and lack of HIV virologic suppression: point-of-care urine drug screen versus self-report. BMC Infect Dis 2014 0.78
91 Association between U.S. state AIDS Drug Assistance Program (ADAP) features and HIV antiretroviral therapy initiation, 2001-2009. PLoS One 2013 0.78
92 Agreement of decision analyses and subsequent clinical studies in infectious diseases. Am J Med 2007 0.77
93 Stability of antituberculosis drugs mixed in food. Clin Infect Dis 2007 0.77
94 Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared to the General Population. J Acquir Immune Defic Syndr 2017 0.76
95 Tuberculosis and HIV. AIDS Clin Care 2002 0.76
96 Superior Glucose Tolerance and Metabolomic Profiles, Independent of Adiposity, in HIV-Infected Women Compared With Men on Antiretroviral Therapy. Medicine (Baltimore) 2016 0.75
97 Treatment of Mycobacterium tuberculosis infection: time to get a move on? Ann Intern Med 2014 0.75
98 Are we ready to shorten the treatment duration for non-cavitary pulmonary tuberculosis? Int J Tuberc Lung Dis 2013 0.75
99 Chronic kidney disease at presentation is not an independent risk factor for AIDS-defining events or death in HIV-infected persons. Clin Nephrol 2013 0.75
100 Weight Gain in Persons with HIV Switched from Efavirenz-based to Integrase Strand Transfer Inhibitor-based Regimens. J Acquir Immune Defic Syndr 2017 0.75
101 When to start HAART: still a controversy. Report from Seattle: the 9th Conference on Retroviruses and Opportunistic Infections (CROI). Hopkins HIV Rep 2002 0.75
102 Associations of CD4+ T-cell count, HIV-1 RNA viral load, and antiretroviral therapy with Kaposi sarcoma risk among HIV-infected persons in the United States and Canada. J Acquir Immune Defic Syndr 2017 0.75
103 When to start HAART, and what to start. Hopkins HIV Rep 2003 0.75
104 Misdiagnosis of HIV infection: implications for universal testing. AIDS 2008 0.75
105 Antiretroviral therapy: when to start & what to start with. Hopkins HIV Rep 2002 0.75
106 Treatment of tuberculosis in the HIV-infected patient. Hopkins HIV Rep 2003 0.75